GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (STU:2VT0) » Definitions » Investments And Advances

Lipocine (STU:2VT0) Investments And Advances : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Lipocine Investments And Advances?

Lipocine's Investments And Advances for the quarter that ended in Dec. 2023 was €0.00 Mil.

Lipocine's annual Investments And Advances declined from Dec. 2021 (€1.79 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Lipocine Investments And Advances Historical Data

The historical data trend for Lipocine's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Investments And Advances Chart

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.79 - -

Lipocine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lipocine Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Lipocine (STU:2VT0) Business Description

Traded in Other Exchanges
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Lipocine (STU:2VT0) Headlines

No Headlines